Merix/Glaxo Cold Sore Cold War Ends With Settlement
This article was originally published in The Tan Sheet
Executive Summary
The cold sore treatment cold war between competing manufacturers Merix Pharmaceutical Corp. and GlaxoSmithKline ended this month when the firms settled their multi-court false advertising dispute after more than four years of litigation
You may also be interested in...
Merix Takes Road Less Traveled To Add Shingles Relief To OTC Monograph
Merix Pharmaceuticals has petitioned FDA to amend the external analgesic and skin protectant OTC monographs, to include an indication for the relief of symptoms of shingles and chicken pox for certain combinations of ingredients
GSK Abreva Ad Claims Lack Supporting Data – Lawsuit
Data from studies measuring the efficacy of GlaxoSmithKline's OTC cold sore treatment Abreva do not substantiate ad claims for the product, Merix Pharmaceutical alleges in a false advertising suit
GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
Advertising claims that GlaxoSmithKline's cold-sore treatment Abreva "speeds healing like a prescription without one" are supported, the National Advertising Division of the Council of Better Business Bureaus concludes after a recent inquiry